Visceral adiposity is associated with the discrepancy between glycated albumin and HbA1c in type 2 diabetes
- PDF / 1,136,912 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 52 Downloads / 217 Views
ORIGINAL ARTICLE
Visceral adiposity is associated with the discrepancy between glycated albumin and HbA1c in type 2 diabetes Saori Maruo1 · Koka Motoyama1 · Tomoe Hirota1 · Yoshinori Kakutani1 · Yuko Yamazaki1 · Tomoaki Morioka1 · Katsuhito Mori2 · Shinya Fukumoto3 · Atsushi Shioi4 · Tetsuo Shoji4 · Masaaki Inaba1 · Masanori Emoto1 Received: 20 October 2019 / Accepted: 5 March 2020 © The Japan Diabetes Society 2020
Abstract Aim We investigated the association of visceral adiposity with glycated albumin (GA) as well as GA/hemoglobin A1c (HbA1c) in type 2 diabetes. Methods One hundred twenty-three patients (68 males, 55 females) with type 2 diabetes were enrolled in this cross-sectional study. Visceral fat area (VFA) was determined using an abdominal dual bioelectrical impedance analysis (dual BIA) instrument. The relationship of VFA with GA and GA/HbA1c was analyzed. Results Simple regression analysis showed that BMI was inversely correlated with GA as well as GA/HbA1c, but not with HbA1c, while VFA had a significant correlation with GA and GA/HbA1c. Furthermore, multiple regression analysis revealed VFA as an independent contributor to GA/HbA1c. These results suggest that visceral adiposity is a primary factor associated with GA and HbA1c level discrepancy in patients with type 2 diabetes. Conclusions GA is a useful indicator for glycemic control, while visceral obesity should also be taken into consideration in type 2 diabetes cases. Keywords Diabetes mellitus · Glycated albumin · Visceral fat area · Obesity
Introduction
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13340-020-00431-z) contains supplementary material, which is available to authorized users. * Koka Motoyama [email protected]‑cu.ac.jp 1
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1‑4‑3, Asahi‑machi, Abeno‑ku, Osaka 545‑8585, Japan
2
Department of Nephrology, Osaka City University Graduate School of Medicine, 1‑4‑3, Asahi‑machi, Abeno‑ku, Osaka 545‑8585, Japan
3
Department of Premier Preventive Medicine, Osaka City University Graduate School of Medicine, 1‑4‑3, Asahi‑machi, Abeno‑ku, Osaka 545‑8585, Japan
4
Department of Vascular Medicine, Osaka City University Graduate School of Medicine, 1‑4‑3, Asahi‑machi, Abeno‑ku, Osaka 545‑8585, Japan
Serum glycated albumin (GA) and hemoglobin A1c (HbA1c) levels have been reported useful for assessment of long-term glycemic control in patients with diabetes mellitus [1, 2], while HbA1c has been shown to serve as an integrated measurement parameter of blood glucose during the most recent 2–3 months [3]. As an alternative, serum GA level has also been utilized, as it has been found useful for obtaining a recent or short-term index of glycemic control, because albumin has a half-life of approximately 19 days in serum [1, 4]. There are several other advantages associated with measuring GA in serum, including the fact that GA is not influenced by some of the physiol
Data Loading...
